| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000017585 |
| Receipt No. | R000020359 |
| Official scientific title of the study | Multicenter, randomized, open-label study to compare immunoglobulin to immunoglobulin plus cyclosporin A combination therapy in patients with severe Kawasaki disease |
| Date of disclosure of the study information | 2015/05/15 |
| Last modified on | 2018/02/05 (Ver. 9) |
| Basic information | ||
| Official scientific title of the study | Multicenter, randomized, open-label study to compare immunoglobulin to immunoglobulin plus cyclosporin A combination therapy in patients with severe Kawasaki disease | |
| Title of the study (Brief title) | KAICA Trial | |
| Region |
|
|
| Condition | |||
| Condition | Severe Kawasaki disease | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | YES | ||
| Objectives | |
| Narrative objectives1 | The objective of this randomized comparative study is to verify whether immunoglobulin (IVIG) + cyclosporin A (CsA) combination therapy as the primary treatment is superior to the standard IVIG treatment in preventing the development of coronary artery abnormalities (CAAs) in pediatric patients with severe Kawasaki disease (KD). |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Frequency of CAAs during the study period (central review of echocardiography data) |
| Key secondary outcomes | [Efficacy]
1)Frequency of CAA at week 4 2)Frequency of treatment resistance (initial treatment unresponsiveness or relapse during the 12 weeks after treatment initiation.) 3)Z scores for the right coronary artery, and the left main coronary trunk and anterior descending artery. 4)Fever duration 5)Changes in body temperature, frequency of defervescence. 6)Change in serum concentration of C reactive protein (CRP). 7)Genotype frequency of ITPKC and CASP3 SNPs. 8)Additional treatment and follow-up treatment. [Safety] 1)Frequency of AEs |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -but assessor(s) are blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | CsA (5 mg/kg/day in 2 divided doses*5days) + IVIG (2 g/kg*1 day] + Aspirin(30 mg/kg/day in 3 divided doses every day) | |
| Interventions/Control_2 | IVIG 2g/kg*1 day + Aspirin 30 mg/kg/day | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Pediatric patients with a diagnosis of KD according to the Kawasaki Disease Diagnostic Guideline (the 5th revised edition).
Patients who meet 5 of the 6 main symptoms below are diagnosed as having KD. 2)Severe KD patients with a risk score of 5 points or higher. The risk score is defined as the sum of all items in the risk-scoring system (5 blood exam data, 2 demographic data of the subjects) developed by Kobayashi et al. Of note, the risk scoring will be performed using a method employed in the previous literature in which the worst values of the blood exam obtained within the acceptable range of time points will be adopted. 3)Age of 4 months or more at the time of signing the informed consent form. 4)Inclusion in the study within 7 days of disease onset. (considering day 1 to be the day when the fever develops.) 5)Informed consent form signed by the patient or a legal guardian. |
|||
| Key exclusion criteria | 1)A history of KD recurrence.
2)CAAs prior to enrolment. 3)No presence of fever prior to enrolment. 4)Suspicion that the symptoms may correspond to a disease other than KD. (haemolytic streptococcal infection, EB virus infection, Yersinia infection, measles or Stevens-Johnson syndrome.) 5)Initiation of IVIG treatment later than 9 days after disease onset. 6)Administration of IVIG within 180 days prior to obtaining informed consent. 7)Treatment with steroids (except external preparations), steroid pulse, biological agents, neutrophil elastase inhibitors, immunosuppressants, or plasmapheresis within 30 days of screening. 8)History of hypersensitivity to CsA preparations, immunoglobulin preparations, or aspirin. 9)Having had treatment with tacrolimus, pitavastatin, rosuvastatin, bosentan, aliskiren, asunaprevir or vaniprevir. 10)Aspartate aminotransferase or, alanine aminotransferase values of 500 IU/L or higher. 11)An estimated glomerular filtration rate of 50 mL/min/1.73 m2 or lower. 12)Presence of an active bacterial infection: septicaemia, meningitis purulenta, peritonitis or bacterial pneumonia. 13)Treatment with other investigational drugs within 12 weeks of study commencement. 14)Others: patients who are judged to be inappropriate for participants of the clinical study for safety reasons by the investigators or the sub-investigators. |
|||
| Target sample size | 172 | |||
| Research contact person | |
| Name of lead principal investigator | Akira Hata |
| Organization | Chiba University Hospital |
| Division name | Division of Medical Genetics |
| Address | Inohana 1-8-1, Chuo-ku, Chiba, Chiba 260-8-670 |
| TEL | 043-222-7171 |
| ahata@faculty.chiba-u.jp | |
| Public contact | |
| Name of contact person | Yasuhisa Fujii |
| Organization | Chiba University Hospital |
| Division name | Chiba Clinical Research Center |
| Address | Inohana 1-8-1, Chuo-ku, Chiba, Chiba 260-8-670 |
| TEL | 043-222-1206 |
| Homepage URL | http://www.chiba-crc.jp/kaica_trial-pc/index.html |
| chibaARO-CRA@ml.chiba-u.jp | |
| Sponsor | |
| Institute | Chiba University Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japan Medical Association |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | YES |
| Study ID_1 | JMA-IIA00174 |
| Org. issuing International ID_1 | Japan Medical Association |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020359 |